149 related articles for article (PubMed ID: 34147047)
1. Clinical characteristics and treatment patterns with histrelin acetate subcutaneous implants vs. leuprolide injections in children with precocious puberty: a real-world study using a US claims database.
Silverman LA; Han X; Huang H; Near AM; Hu Y
J Pediatr Endocrinol Metab; 2021 Aug; 34(8):961-969. PubMed ID: 34147047
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns, health resource utilization and costs among central precocious puberty patients treated with leuprolide or histrelin: an examination of the commercial and Medicaid populations.
Klein KO; Soliman AM; Bonafede M; Nelson JK; Grubb E
J Med Econ; 2020 Apr; 23(4):407-414. PubMed ID: 31766907
[No Abstract] [Full Text] [Related]
3. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424.
Drugs R D; 2005; 6(1):53-5. PubMed ID: 15801868
[TBL] [Abstract][Full Text] [Related]
4. Trends in the use of puberty blockers among transgender children in the United States.
Lopez CM; Solomon D; Boulware SD; Christison-Lagay ER
J Pediatr Endocrinol Metab; 2018 Jun; 31(6):665-670. PubMed ID: 29715194
[TBL] [Abstract][Full Text] [Related]
5. Health Care Utilization and Economic Burden in Patients with Central Precocious Puberty: An Assessment of the Commercially Insured and Medicaid Populations.
Klein K; Soliman AM; Bonafede M; Nelson JK; Grubb E
J Manag Care Spec Pharm; 2019 Jul; 25(7):836-846. PubMed ID: 31232203
[TBL] [Abstract][Full Text] [Related]
6. Histrelin for central precocious puberty-a single surgeon experience.
Rosati S; Maarouf R; Brown K; Poppe M; Parrish D; Haynes J; Lanning D
J Surg Res; 2015 Oct; 198(2):355-9. PubMed ID: 25899147
[TBL] [Abstract][Full Text] [Related]
7. The histrelin implant: a novel treatment for central precocious puberty.
Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D
J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.
Silverman LA; Neely EK; Kletter GB; Lewis K; Chitra S; Terleckyj O; Eugster EA
J Clin Endocrinol Metab; 2015 Jun; 100(6):2354-63. PubMed ID: 25803268
[TBL] [Abstract][Full Text] [Related]
10. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
Gillis D; Karavani G; Hirsch HJ; Strich D
J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
[TBL] [Abstract][Full Text] [Related]
11. A single histrelin implant is effective for 2 years for treatment of central precocious puberty.
Lewis KA; Goldyn AK; West KW; Eugster EA
J Pediatr; 2013 Oct; 163(4):1214-6. PubMed ID: 23809043
[TBL] [Abstract][Full Text] [Related]
12. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty.
Lewis KA; Eugster EA
J Pediatr; 2013 Mar; 162(3):562-5. PubMed ID: 23040793
[TBL] [Abstract][Full Text] [Related]
13. Optimizing pediatric histrelin implantation to improve success rates in clinic without sedation.
Krishna V; Lee SL; DeUgarte DA
J Pediatr Endocrinol Metab; 2021 Nov; 34(11):1443-1448. PubMed ID: 34407329
[TBL] [Abstract][Full Text] [Related]
14. Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists.
Miller BS; Shukla AR
Clin Ther; 2010 Sep; 32(10):1749-51. PubMed ID: 21194598
[TBL] [Abstract][Full Text] [Related]
15. Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty.
Ray LA; Eckert GJ; Eugster EA
J Pediatr Endocrinol Metab; 2023 Mar; 36(3):309-312. PubMed ID: 36625262
[TBL] [Abstract][Full Text] [Related]
16. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
Klein KO; Freire A; Gryngarten MG; Kletter GB; Benson M; Miller BS; Dajani TS; Eugster EA; Mauras N
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3660-71. PubMed ID: 32738042
[TBL] [Abstract][Full Text] [Related]
17. Surgical and anesthetic considerations in histrelin capsule implantation for the treatment of precocious puberty.
Davis JS; Alkhoury F; Burnweit C
J Pediatr Surg; 2014 May; 49(5):807-10. PubMed ID: 24851775
[TBL] [Abstract][Full Text] [Related]
18. Treatment and outcomes of precocious puberty: an update.
Fuqua JS
J Clin Endocrinol Metab; 2013 Jun; 98(6):2198-207. PubMed ID: 23515450
[TBL] [Abstract][Full Text] [Related]
19. Resumption of puberty in girls and boys following removal of the histrelin implant.
Fisher MM; Lemay D; Eugster EA
J Pediatr; 2014 Apr; 164(4):912-916.e1. PubMed ID: 24433825
[TBL] [Abstract][Full Text] [Related]
20. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
